The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.

A sortable and searchable table of FDA original PMAs and panel-track supplements approved in calendar year 2016, updated monthly. Latest update: approvals through June 30.

Approved as a long-term treatment option for obese patients with a body-mass index of 35 to 55, Aspire Bariatrics is positioning its AspireAssist device as a less-invasive alternative to bariatric surgery in the population of morbidly obese individuals who are most often recommended for a procedure. The system includes an endoscopically implanted tube and a port used by the patient to drain contents of the stomach and reduce calories absorbed.

It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and Aspire Bariatrics submitted an application for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.